Listed

Sunshine Biopharma Inc.: Form 10-Q for the period ended Mar 31, 2016

Filed with the SEC on May 9, 2016 and accepted by EDGAR at May 9, 2016, 16:09 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-01-01 to 2016-03-31$0us-gaap:SalesRevenueGoodsNet
Operating income3 months2016-01-01 to 2016-03-31−$69.7kus-gaap:OperatingIncomeLoss
Interest expense3 months2016-01-01 to 2016-03-31$7.0kus-gaap:InterestExpense
Net income3 months2016-01-01 to 2016-03-31−$305.3kus-gaap:NetIncomeLoss
Basic EPS3 months2016-01-01 to 2016-03-31$0.00us-gaap:EarningsPerShareBasic
Operating cash flow3 months2016-01-01 to 2016-03-31−$81.6kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2016-03-31$123.3kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-03-31$226.5kus-gaap:AssetsCurrent
Total assetsAt period end2016-03-31$830.6kus-gaap:Assets
Current liabilitiesAt period end2016-03-31$1.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-03-31$1.2mus-gaap:Liabilities
Shareholders' equityAt period end2016-03-31−$355.4kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-16-007274. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.